Fundraising FoxAtlas Venture — 2015 Investments
11 investments dated 2015 · listed companies and verified rows first · show all
Editas Medicine develops gene editing medicines using CRISPR/Cas9 and CRISPR/Cas12a technology to treat serious diseases including blood disorders, cardiovascular conditions, and cancer.
BiotechDeep TechMedical DevicesCambridge, US
Feng Zhang(Founder)inGeorge Church(Scientific Founder, Professor of Genetics, Harvard University and MIT)inKeith Joung(Scientific Founder, Professor of Pathology, Harvard Medical School)inDavid Liu(Scientific Founder, Professor of Chemistry and Chemical Biology, Harvard University)inKatrine Bosley(Executive Officer, Director)inVic Myer(Executive Officer)in
Board seatKevin Bitterman· per SEC Form D · $120M raise · filed Aug 2015
Co-investorsEcoR1 CapitalGV (Google Ventures)Sofinnova VenturesViking GlobalDeerfield Management CompanyFlagship Ventures+2 more
Intellia Therapeutics develops in vivo and ex vivo CRISPR/Cas9 gene editing therapies aimed at treating the root causes of severe genetic diseases, with lead candidates for hereditary angioedema and ATTR amyloidosis.
BiotechDeep TechHealthtechCambridge, US
Nessan Bermingham(Founder)inJennifer Doudna(Founder)Jose Rivera(Executive Officer)inJohn Leonard(President and Chief Executive Officer)inJames Basta(Executive Vice President, General Counsel and Corporate Secretary)inEdward Dulac(Executive Vice President, Chief Financial Officer)in
Board seatJean-François Formela· per SEC Form D
Co-investorsage1Avoro Capital AdvisorsEcoR1 CapitalForesite CapitalOrbiMedRidgeback Capital+1 more
A biopharmaceutical company developing an artificial intelligence infrastructure platform designed for on-premises deployment in biotechnology and pharmaceutical research environments, serving biotech firms and pharma companies seeking secure access to advanced AI capabilities while retaining control over proprietary biological data; the company is also evaluating strategic alternatives for its legacy mesenchymal stem cell secretome assets after discontinuing its lead rare eye disease therapeutic program.
BiotechArlington, US
Justin Hanes(Director)inKevin Pojasek(Executive Officer)inDarius Kharabi(Executive Officer)inTodd Bazemore(Executive Officer)inMark Iwicki(Executive Officer, Director)inMary Reumuth(Executive Officer)in
Board seatKevin Bitterman· per SEC Form D · $7M raise · filed Aug 2015
Co-investorsLongitude CapitalSR One Capital ManagementWellington ManagementYsios CapitalLux CapitalRA Capital+1 more
Neuronetics manufactures and sells the NeuroStar Advanced Therapy System, a transcranial magnetic stimulation device used in office-based treatment of major depressive disorder and other mental health conditions, along with operating a network of treatment centers that provide both NeuroStar therapy and esketamine treatment to patients.
HealthtechMalvern, US
Mark R. Bausinger(Executive Officer)inChristopher Thatcher(Executive Officer, Director)inDaniel L. Reuvers(President and Chief Executive Officer)
BoardStephen Campe(Director)Robert Kuhling(Director)Liam Ratcliffe(Director)
Board seatKevin Bitterman· per SEC Form D · $34.3M raise · filed May 2015
Co-investors1315 CapitalAscension VenturesCHV CapitalGE Ventures
BiotechCambridge, US
Rick Lundberg(Executive Officer)George P. Vlasuk(Executive Officer, Director)in
BoardJean-Francois Formela(Director)inAlan Crane(Director)inMarian Nakada(Director)inBrian Gallagher(Director)in
Board seatKevin BittermanJean-François Formela· per SEC Form D
Co-investorsage1Brace PharmaSanofi VenturesPolaris PartnersSR One Capital Management
BiotechCambridge, US
Robert Prentiss(Executive Officer)Ronald C. Renaud, Jr.(Executive Officer, Director)Thomas McCauley(Executive Officer)
BoardBrian Gallagher(Director)Jean- Francois Formela(Director)inJoshua Resnick(Director)
Board seatJean-François Formela· per SEC Form D
Co-investorsPfizer Venture Investments
Influitive provides a SaaS platform and professional services for customer advocate marketing, helping companies discover and mobilize their customer advocates to drive sales and customer lifetime value.
Marketing TechMedia & EntertainmentSaaS
Mark Organ(Founder)inPuneet ArorainRich Stollerin
Co-investors500 GlobalExtreme Venture PartnersExtreme Venture Partners LLPGolden VenturesHummer Winblad Venture Partners (HWVP)Illuminate Ventures+8 more
Integral Ad Science provides advertising verification and quality assurance solutions for digital advertisers and platforms.
AdTechAI & Machine LearningData & InfrastructureMarketing TechNew York, US
Lidiane Jones(Chief Executive Officer)inAmit Chaturvedi(Chief Operating Officer)inSrishti Gupta(Chief Product Officer)inThomas Joseph(Chief Technology Officer)inLisa Nadler(Chief Human Resources Officer)inYossi Almani(Chief Legal Officer)in
Co-investorsAccompliceAugust CapitalCross Creek AdvisorsFounder CollectiveGolub GrowthLobby Capital+6 more
PillPack is a full-service pharmacy that organizes and delivers medications to customers, managing automatic refills and coordinating directly with doctors and insurance providers.
Digital HealthHealthtechManchester, US
Timothy Parker(Chief Executive Officer, Director)inElliot Cohen(Chief Technology Officer, Director)inTJ Parker(Founder)in
BoardDavid Frankel(Director)inJon Karlen(Director)Fred Destin(Director)
Co-investorsAccelAccompliceACME CapitalBoxGroupCRV (Charles River Ventures)Entrée Capital+12 more
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.